Gordon AN et al. (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95: 1–8
Since cure is unlikely in most patients with recurrent ovarian cancer, treatments are aimed at prolonging survival while maintaining quality of life. A trend towards improved survival has been demonstrated in patients treated with pegylated liposomal doxorubicin compared with topotecan. Gordon et al. have recently completed their analysis of long-term survival data from the same study.
The analysis covered 474 women with epithelial ovarian cancer who either failed to respond to first-line, platinum-based chemotherapy or recurred after treatment. Patients subsequently randomized to pegylated liposomal doxorubicin (n = 239) had significantly better survival than those treated with topotecan (n = 235). Median survival was 62.7 and 59.7 weeks for the two groups, respectively. This corresponded to an 18% reduction in the risk of death in the pegylated liposomal doxorubicin group. Patients with platinum-sensitive disease (i.e. those who responded to initial treatment and were then progression-free for >6 months) were analyzed separately. These women showed a more pronounced survival benefit when treated with pegylated liposomal doxorubicin, with a 30% reduction in the risk of death compared with those in the topotecan group. For patients with platinum-refractory disease, there was no significant difference in survival between the two treatment groups.
In conclusion, pegylated liposomal doxorubicin significantly prolonged survival in this long-term study, compared with topotecan. The authors suggest that the drug should be treatment of choice for patients with relapsed ovarian cancer.
Rights and permissions
About this article
Cite this article
Improved long-term survival in ovarian cancer. Nat Rev Clin Oncol 1, 61 (2004). https://doi.org/10.1038/ncponc0031
Issue Date:
DOI: https://doi.org/10.1038/ncponc0031